Abstract
The theoretical diffraction-limit of resolution for ultrasound imaging has recently been bypassed in-vitro and in-vivo. However, in the context of ultrasound therapy, the precision of therapeutic beams remains bound to the half-wavelength limit. By combining acoustic vaporization of composite droplets and rapid ultrasound monitoring, we demonstrate that the ultrasound drug-delivery can be restricted to a subwavelength zone. Moreover, two release zones closer than the wavelength/4 can be distinguished both optically and through ultrafast ultrasound localization microscopy. This proof-of-concept let us envision the possibility to treat specific tissues more precisely without compromising on the penetration depth of the ultrasound wave.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
